Shorts

CancerNetwork® spoke with Marc Lehrer Greenwald, MD, about the rising incidence of colorectal cancer among younger patients.

1:09

How a Short Exam Identified a Colorectal Cancer in a Patient in Their 40s

6 months ago

Marc Lehrer Greenwald, MD

In a discussion with CancerNetwork®, Zhaohui Liao Arter, MD, spoke about updated analysis findings from the phase 2 eNRGy trial (NCT02912949) assessing zenocutuzumab-zbco (Bizengri) beyond initial disease progression among patients with NRG1 fusion-positive non–small cell lung cancer.

0:48

Updated Zenocutuzumab Analysis Reveals “Striking” Outcomes in NRG1+ NSCLC

6 months ago

Zhaohui Liao Arter, MD

1:00

The Truth About GLP-1s: Assessing the Risk of Medullary Thyroid Cancer in Humans

6 months ago

Gary Clayman, MD

Marwan G. Fakih, MD, analyzed the current treatment landscape for patients with later-line metastatic colorectal cancer.

1:17

What Are the Best Treatment Options for Patients with Later-Line mCRC?

6 months ago

Marwan G. Fakih, MD

Zin Myint, MD, compared the incidence of AEs among patients with high-risk prostate cancer treated with pembrolizumab and radiotherapy alone vs with olaparib in a phase 2 study.

0:57

Pembro/RT ± Olaparib Shows Similar Safety in High-Risk Prostate Cancer

6 months ago

Zin Myint, MD

In this video, we asked Molly Ingersoll, PhD, a couple of fun, personal questions at ASCO GU.

0:46

GU Gemstones: Molly Ingersoll, PhD

6 months ago

Molly Ingersoll, PhD

$Sagar Lonial, MD, FACP, FASCO, spoke with CancerNetwork® about the FDA’s acceptance of a new drug application for iberdomide plus daratumumab (Darzalex) and dexamethasone for patients with relapsed/refractory multiple myeloma, detailing how a potential approval may impact the treatment paradigm.$

0:46

Iberdomide Might Expand Tool Belt for Finding a Multiple Myeloma Cure

6 months ago

Sagar Lonial, MD, FACP, FASCO

In this pilot "Roman's Rundown" video, Roman introduces KOLs he spoke with at ASCO GU Day 2 and gives a quick, time-lapsed glimpse of his run that morning, which goes right by the conference building.

0:39

Roman's Rundown: ASCO GU Day 2

6 months ago

Roman Fabbricatore

0:55

The Technical Risks of Faster Radiation Treatments in Breast Cancer

6 months ago

Sunil W. Dutta, MD

Jason Molitoris, MD, PhD, discussed the role of intensity-modulated proton therapy as a new standard of care among patients undergoing treatment for oropharyngeal squamous cell carcinoma.

0:38

Defining a New Standard of Care in the OPSCC Treatment Paradigm

6 months ago

Jason K. Molitoris, MD, PhD

0:40

Managing Immunotherapy-Related Toxicities in Breast Cancer

6 months ago

Sarah Poland, MD

Gwen Nichols, MD, spoke with CancerNetwork® about findings from the phase 3 Precision-T trial (NCT04013685) assessing Orca-T vs conventional allogenic hematopoietic stem cell transplantation strategies among patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome.

0:47

Orca-T Reduces the “Costs” of Transplantation in Blood Cancers

6 months ago

Gwen Nichols, MD

In a conversation with CancerNetwork®, Ashkan Emadi, MD, PhD, discussed early findings from a phase 2 trial (NCT07222579) assessing subcutaneous blinatumomab (Blincyto) among patients with CD19-positive mixed phenotype acute leukemia (MPAL), a rare acute leukemia.

0:41

Trial in Rare Leukemia Shows “Unprecedented Result” With Blinatumomab

6 months ago

Ashkan Emadi, MD, PhD

0:59

Can Preoperative Radiation Help Patients Skip Breast Cancer Surgery?

6 months ago

Parul Barry

Monzr M. Al Malki, MD, outlined the advantages TRX103, a novel allogeneic CD4 T-cell therapy, offers for HLA-mismatched hematopoietic cell transplant recipients with lymphoma.

0:39

What Advantages Does TRX103 Provide in HLA-Mismatched Lymphoma?

6 months ago

Monzr Al Malki, MD

Mauro Cives, MD, discussed the advantage a T-cell receptor-based approach affords for patients undergoing treatment for pancreatic neuroendocrine tumors, particularly based on an ability to recognize major histocompatibility complex-presenting intracellular peptides.

1:30

Uncovering the Unique Advantage of a TCR-Based Approach in Pancreatic NETs

6 months ago

Mauro Cives, MD

$In a discussion with CancerNetwork®, Saad Z. Usmani, MD, MBA, FACP, FASCO, outlined the mechanism of action of gintemetostat (KTX-1001), a novel small molecule inhibitor under evaluation in a phase 1 trial (NCT05651932) among patients with relapsed/refractory multiple myeloma.$

0:32

How Does KTX-1001 Target Genetic Abnormalities in Multiple Myeloma?

6 months ago

Saad Z. Usmani, MD, MBA, FACP

A Potential Breakthrough in Sarcoma Treatment

6 months ago

Seth M. Pollack, MD

0:32

How AI Is Revolutionizing Electronic Health Records

6 months ago

Sunil W. Dutta, MD

Meet the team behind the articles, interviews, and shorts posted on CancerNetwork and published in ONCOLOGY.

0:36

Meet The CancerNetwork Team

6 months ago

Cancer Network Staff

Patrick Borgen, MD, discussed the impact that MRD and ctDNA have played on treatment selection for breast cancer, particularly regarding surgery.

1:17

Examining the Impact of ctDNA on Breast Cancer Surgery

6 months ago

Patrick I. Borgen, MD

0:50

Patient-Centered Care Should Drive Sarcoma Research

7 months ago

Emily J. Papai, MD

Suzann Duan, PhD, discussed the potential link between immunosenescence and the emergence of immunologically “cold” tumor microenvironments in GEP-NETS.

1:21

Is There a Link Between Immunosenescence and “Immune Cold” TMEs in NETs?

7 months ago

Suzann Duan, PhD

In a discussion with CancerNetwork®, Ram Prakash Thirugnanasambandam, MBBS, spoke about a manuscript he published in the November/December 2025 issue of the journal ONCOLOGY® focusing on the role that artificial intelligence (AI) can play in palliative care and hematologic malignancies.

0:55

Implementing AI as a Supportive Tool in Palliative Oncological Care

7 months ago

Ram Prakash Thirugnanasambandam, MBBS

Mauro Cives, MD, discussed a surprising finding in his research, which won an investigator award from the Neuroendocrine Tumor Research Foundation.

1:07

Some TILs May Exploit Antitumor Activity in Pancreatic NETs

7 months ago

Mauro Cives, MD

$Shambavi Richard, MD, spoke with CancerNetwork® about findings from the phase 1b portion of the DURGA-1 trial (NCT05850234) assessing AZD0120, a novel BCMA/CD19 dual-targeting cellular therapy, among those with relapsed/refractory multiple myeloma.$

0:39

AZD0120 Shows “Excellent” Response Rates in R/R Multiple Myeloma

7 months ago

Shambavi Richard, MD

Dominique Rash, MD, highlighted what patient factors and characteristics guide how radiation oncologists coordinate utilizing radiation with systemic therapy for patients with inoperable endometrial cancer.

0:56

Sequencing Radiation With Systemic Therapy in Inoperable Endometrial Cancer

7 months ago

Dominique Rash, MD

0:41

Why Survivorship is the Next Phase of Cancer Research

7 months ago

Fumiko Chino, MD

$In a conversation with CancerNetwork® at the 2026 American College of Radiation Oncology (ACRO) Summit, Pranshu Mohindra, MD, discussed the evolution of hypofractionated radiotherapy in the lung cancer field, which may help expedite the treatment process for patients$

0:46

How Has Hypofractionation Made Lung Cancer Radiotherapy More Convenient?

7 months ago

Pranshu Mohindra, MD